Related Experiment Video
Updated: May 1, 2026
Phenotypic Characterization of Macrophages from Rat Kidney by Flow Cytometry
Published on: October 18, 2016
Alternatively activated macrophages as therapeutic agents for kidney disease: in vivo stability is a key factor
Senthilkumar Alagesan1, Matthew D Griffin1
1Regenerative Medicine Institute (REMEDI) and College of Medicine, Nursing and Health Sciences, National University of Ireland, Galway, Ireland.
Abstract:
Infusing ex vivo-generated alternatively activated macrophages (AAM) has shown promise in experimental systems as a therapeutic strategy for inflammatory kidney disease. In the mouse Adriamycin nephropathy model, however, Cao et al. report that AAM derived from bone marrow precursors fail to ameliorate disease severity. Absence of the anticipated protective effect resulted from a loss of macrophage anti-inflammatory (M2) phenotype following trafficking to injured kidney-an effect that was mediated by localized colony-stimulating factor-1-dependent macrophage proliferation.
Insights
Alternatively activated macrophages (AAM) infusion failed to protect against kidney injury in mice. Macrophages lost their anti-inflammatory (M2) phenotype in the injured kidney due to local proliferation.
Area of Science:
- Immunology
- Nephrology
- Regenerative Medicine
Background:
- Alternatively activated macrophages (AAM) are recognized for their anti-inflammatory properties.
- AAM infusion shows therapeutic potential for inflammatory kidney diseases in preclinical models.
- Adriamycin nephropathy is a common model for studying kidney inflammation and injury.
Purpose of the Study:
- To investigate the therapeutic efficacy of ex vivo-generated AAM in a mouse model of Adriamycin-induced nephropathy.
- To determine the fate and functional phenotype of infused AAM within the injured kidney microenvironment.
Main Methods:
- Bone marrow-derived macrophages were differentiated into AAM ex vivo.
- AAM were infused into mice subjected to Adriamycin nephropathy.
- Macrophage phenotype and proliferation were assessed in kidney tissue post-infusion.
Main Results:
- Infused AAM failed to ameliorate disease severity in the Adriamycin nephropathy model.
- Adopted macrophages exhibited a loss of their anti-inflammatory (M2) phenotype.
- Localized colony-stimulating factor-1-dependent macrophage proliferation was observed in the injured kidneys.
Conclusions:
- The therapeutic benefit of AAM infusion is limited in this kidney injury model.
- In vivo conditions within the injured kidney promote phenotypic and functional alterations in infused macrophages.
- Macrophage proliferation mediated by local factors may counteract the intended therapeutic effects of AAM.
